AG真人官方

STOCK TITAN

AG真人官方-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical鈥檚 RECELL庐 System

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

AVITA Medical (NASDAQ: RCEL) announced compelling real-world data demonstrating significant benefits of its RECELL庐 System in burn treatment. The analysis from the U.S. national burn registry showed that RECELL reduces hospital length of stay by 36% compared to traditional skin grafts in adults with deep second-degree burns.

The study of 741 adults revealed RECELL-treated patients experienced an average 5.6-day reduction in hospital stay, potentially saving over $42,000 per patient in costs. The system enables hospitals to treat 13 more patients per bed annually. RECELL requires 97.5% less skin compared to traditional grafts while improving donor site healing, pain, and scarring.

AVITA Medical (NASDAQ: RCEL) ha presentato dati real-world significativi che mostrano i benefici del suo sistema RECELL庐 nel trattamento delle ustioni. L'analisi del registro nazionale delle ustioni degli Stati Uniti ha evidenziato che RECELL riduce la durata del ricovero del 36% rispetto ai trapianti di pelle tradizionali negli adulti con ustioni di secondo grado profondo.

Lo studio su 741 adulti ha rilevato che i pazienti trattati con RECELL hanno avuto in media una riduzione della degenza di 5,6 giorni, con un potenziale risparmio di oltre $42.000 per paziente in termini di costi. Il sistema permette agli ospedali di trattare 13 pazienti in pi霉 per letto all'anno. RECELL richiede il 97,5% in meno di pelle rispetto ai trapianti tradizionali e migliora la guarigione del sito donatore, il dolore e le cicatrici.

AVITA Medical (NASDAQ: RCEL) anunci贸 datos del mundo real que demuestran beneficios significativos de su sistema RECELL庐 en el tratamiento de quemaduras. El an谩lisis del registro nacional de quemaduras de EE. UU. mostr贸 que RECELL reduce la duraci贸n de la hospitalizaci贸n en un 36% en comparaci贸n con los injertos de piel tradicionales en adultos con quemaduras de segundo grado profundas.

El estudio, con 741 adultos, revel贸 que los pacientes tratados con RECELL experimentaron una reducci贸n media de la estancia de 5,6 d铆as, con un ahorro potencial de m谩s de $42,000 por paciente. El sistema permite a los hospitales tratar 13 pacientes m谩s por cama al a帽o. RECELL requiere un 97,5% menos de piel frente a los injertos tradicionales y mejora la cicatrizaci贸n del sitio donante, el dolor y las cicatrices.

AVITA Medical (NASDAQ: RCEL)電� 頇旍儊 旃橂鞐愳劀 RECELL庐 鞁滌姢韰滌潣 鞙犾潣氙疙暅 鞁れ牅 雿办澊韯� 瓴瓣臣毳� 氚滍憸頄堨姷雼堧嫟. 氙戈淡 甑皜 頇旍儊 霌彪靻� 攵勳劃鞐� 霐半ゴ氅� RECELL鞚 鞁秬 2霃� 頇旍儊 靹膘澑 頇橃瀽鞐愳劀 旮办〈 頂茧秬 鞚挫嫕鞐� 牍勴暣 鞛呾洂 旮瓣皠鞚� 36% 雼稌頄堨姷雼堧嫟.

741氇呾潣 靹膘澑鞚� 雽靸侅溂搿� 頃� 鞐瓣惮鞐愳劀 RECELL搿� 旃橂氚涭潃 頇橃瀽電� 韽夑窢 鞛呾洂 旮瓣皠鞚� 5.6鞚� 雼稌霅橃柎 頇橃瀽雼� 鞛犾灛鞝侅溂搿� $42,000 鞚挫儊鞚� 牍勳毄鞚� 鞝堦皭頃� 靾� 鞛堧姅 瓴冹溂搿� 雮橅儉雮姷雼堧嫟. 鞚� 鞁滌姢韰滌潉 靷毄頃橂┐ 氤戩洂鞚 氤戩儊雼� 鞐瓣皠 13氇� 雿� 毵庫潃 頇橃瀽毳� 旃橂頃� 靾� 鞛堨姷雼堧嫟. RECELL鞚 旮办〈 鞚挫嫕氤措嫟 97.5% 鞝侅潃 頂茧秬毳� 頃勳殧搿� 頃橂┌ 旮办 攵鞙勳潣 旃橃湢, 韱奠 氚� 頋夗劙 臧滌劆鞐愲弰 霃勳泙鞚� 欷嶋媹雼�.

AVITA Medical (NASDAQ: RCEL) a annonc茅 des donn茅es r茅elles convaincantes montrant des b茅n茅fices significatifs de son syst猫me RECELL庐 dans le traitement des br没lures. L'analyse du registre national des br没lures aux 脡tats-Unis a montr茅 que RECELL r茅duit la dur茅e d'hospitalisation de 36% par rapport aux greffes cutan茅es traditionnelles chez les adultes atteints de br没lures profondes du second degr茅.

L'茅tude men茅e sur 741 adultes a r茅v茅l茅 que les patients trait茅s par RECELL ont b茅n茅fici茅 en moyenne d'une r茅duction de s茅jour de 5,6 jours, permettant potentiellement d'茅conomiser plus de 42 000 $ par patient. Le syst猫me permet aux h么pitaux de traiter 13 patients suppl茅mentaires par lit et par an. RECELL n茅cessite 97,5 % moins de peau que les greffes traditionnelles tout en am茅liorant la cicatrisation du site donneur, la douleur et les cicatrices.

AVITA Medical (NASDAQ: RCEL) hat 眉berzeugende AG真人官方-World-Daten ver枚ffentlicht, die deutliche Vorteile seines RECELL庐-Systems bei der Behandlung von Verbrennungen zeigen. Die Analyse des US-nationalen Brandregisters ergab, dass RECELL die Krankenhausverweildauer bei Erwachsenen mit tiefen zweitgradigen Verbrennungen um 36% gegen眉ber herk枚mmlichen Hauttransplantaten reduziert.

Die Studie mit 741 Erwachsenen zeigte, dass RECELL-behandelte Patienten im Durchschnitt eine Reduktion der Aufenthaltsdauer um 5,6 Tage erlebten, was potenziell 眉ber $42.000 pro Patient an Kosten einspart. Das System erm枚glicht es Krankenh盲usern, pro Bett j盲hrlich 13 weitere Patienten zu behandeln. RECELL ben枚tigt 97,5% weniger Haut als traditionelle Transplantate und verbessert die Heilung der Entnahmestelle, Schmerzen und Narbenbildung.

Positive
  • 36% reduction in hospital length of stay compared to traditional treatment
  • Cost savings exceeding $42,000 per patient
  • Increased hospital efficiency with capacity for 13 more patients per bed annually
  • 97.5% less skin required compared to traditional grafts
  • Higher proportion of patients discharged directly home
Negative
  • None.

Insights

RECELL system shows remarkable 36% shorter hospital stays, $42,000 savings per patient, and increased hospital efficiency in burn treatment.

The real-world data from the U.S. national burn registry demonstrates compelling economic benefits for AVITA Medical's RECELL System. The 36% reduction in hospital length of stay (LOS) translates to approximately $42,000 in cost savings per patient鈥攁 substantial figure in healthcare economics terms.

This analysis involved a matched cohort of 741 adult patients, with 247 receiving RECELL treatment and 494 receiving traditional split-thickness skin grafts. The 5.6-day reduction in hospitalization is statistically significant (p < 0.0001) and represents meaningful clinical improvement.

Beyond direct cost savings, the operational efficiency gains are noteworthy. Hospitals could potentially treat 13 additional patients annually per bed using RECELL versus traditional methods. This throughput improvement is particularly valuable given that U.S. burn cases consumed over 110,000 ICU days in 2023, costing more than $676 million.

The clinical advantages of RECELL requiring 97.5% less donor skin while improving healing outcomes creates a compelling value proposition. With rising healthcare costs and capacity constraints, interventions that simultaneously improve clinical outcomes, reduce resource utilization, and lower costs represent the ideal healthcare economic trifecta that payors, providers, and hospital administrators seek when making technology adoption decisions.

From a clinical perspective, these findings represent a significant advancement in burn care. The 36% reduction in hospital stay isn't just an economic metric鈥攊t signifies substantially faster healing and recovery for patients with deep partial thickness burns.

The registry data is particularly valuable because it reflects real-world outcomes rather than controlled trial conditions. The matched analysis methodology (247 RECELL patients vs. 494 STSG patients) strengthens the validity of these findings by controlling for potential confounding variables.

Most telling is the higher proportion of RECELL-treated patients discharged directly home, indicating better overall recovery trajectories. This suggests patients experience improved functional outcomes that enable them to bypass extended rehabilitation settings.

The technical advantages of RECELL鈥攃reating an autologous skin cell suspension requiring 97.5% less donor skin鈥攁ddresses one of the most challenging aspects of burn care: limited donor site availability. This translates to significantly improved donor site healing, reduced pain, and decreased scarring compared to traditional grafting techniques.

For a burn unit managing multiple patients with varying burn severities, these benefits compound. Reduced length of stay means decreased risk of hospital-acquired complications, lower pain medication requirements, earlier mobilization, and potentially better long-term psychological outcomes for patients鈥攁ll critical factors in comprehensive burn care that go beyond the economic advantages.

  • Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin grafting

  • More than $42,000 per patient cost savings, together with improved patient throughput, support operational and economic value
  • Presented at the 2025 European Burn Association Congress in Berlin, Germany

VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- 聽AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today reaffirmed real-world data from the U.S. national burn registry demonstrating that the use of the RECELL庐 System significantly reduces hospital length of stay (LOS) by an average of 36% compared to traditional split thickness skin grafts (STSG) in adult patients with deep partial thickness (second degree) burns affecting up to 30% total body surface area. A greater proportion of RECELL-treated patients were discharged directly home, indicating improved recovery trajectories.

Victoria Miles, EMTP, MD, of Louisiana State University Health and Sciences Center, presented the results of this research today at the 2025 European Burn Association Congress in Berlin, Germany: 鈥淭hese findings support the role of RECELL as a clinically validated, cost-effective option in modern burn management, and highlight the impact on patient outcomes, hospital efficiency, and resource utilization.鈥�

RECELL harnesses the regenerative properties of a patient鈥檚 own skin to create an autologous skin cell suspension autograft, enabling clinicians to deliver a transformative solution at the point of care. In a matched analysis of 741 adults from the Burn Care Quality Platform registry, patients treated with RECELL (n=247) experienced an average 5.6-day reduction in hospital LOS, a 36% decrease compared to those treated with STSG (n=494; p < 0.0001).

The reduction in LOS achieved upon the use of RECELL is not only clinically meaningful but also economically impactful. Based on an estimated average daily inpatient bed cost of $7,554, the use of RECELL is associated with potential per patient cost savings exceeding $42,000, exclusive of procedure and rehabilitation costs. Furthermore, the reduction in LOS may enable hospitals to treat 13 more patients per bed annually compared to treatment with STSG alone.

Amid a growing need to reduce the burden of burn care on hospital systems, the study鈥檚 findings are particularly compelling. In 2023 alone, U.S. burn cases consumed more than 110,000 ICU days, costing in excess of US$676 million, according to the 2024 ABA Annual Burn Injury Summary Report.

鈥淭he results from this real-world analysis underscore the transformative potential of RECELL in reducing hospitalization time and improving care efficiency,鈥� said Jim Corbett, Chief Executive Officer of AVITA Medical. 鈥淲hen you consider use of RECELL in deep-partial thickness burns requires 97.5% less skin with significantly improved donor site healing, pain, and scarring, compared to split-thickness skin graft1, these insights reaffirm our commitment to delivering clinically meaningful solutions that benefit patients, providers, and the broader healthcare system.鈥�

About AVITA Medical, Inc.

AVITA Medical庐 is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL庐 System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient鈥檚 own skin to create Spray-On Skin鈩� Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm庐, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx鈩�, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO庐, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit鈥�.

Sources:

  1. Holmes Iv JH, Molnar JA, Carter JE, Hwang J, Cairns BA, King BT, Smith DJ, Cruse CW, Foster KN, Peck MD, Sood R, Feldman MJ, Jordan MH, Mozingo DW, Greenhalgh DG, Palmieri TL, Griswold JA, Dissanaike S, Hickerson WL. A Comparative Study of the ReCell庐 Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. J Burn Care Res. 2018 Aug 17;39(5):694-702. doi: 10.1093/jbcr/iry029. PMID: 29800234; PMCID: PMC6097595.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渕ay,鈥� 鈥減otential,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: industry market conditions; failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; the conduct or outcome of pre-clinical or clinical (human) studies; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company鈥檚 control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 鈥淩isk Factors鈥� section of the Company鈥檚 latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
|

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.


FAQ

What are the key benefits of AVITA Medical's RECELL System for burn treatment?

The RECELL System reduces hospital stays by 36%, saves over $42,000 per patient, requires 97.5% less skin than traditional grafts, and improves donor site healing, pain, and scarring.

How much shorter are hospital stays with RECELL compared to traditional skin grafts?

Patients treated with RECELL experience an average 5.6-day reduction in hospital length of stay, representing a 36% decrease compared to traditional split thickness skin grafts.

What is the economic impact of RECELL System on hospitals?

RECELL enables hospitals to save over $42,000 per patient in bed costs and treat 13 more patients per bed annually, significantly improving operational efficiency.

How many patients were included in the RECELL System study?

The study analyzed 741 adults from the Burn Care Quality Platform registry, with 247 patients treated with RECELL and 494 patients treated with traditional skin grafts.

What types of burns can be treated with AVITA Medical's RECELL System?

The RECELL System is used to treat deep partial thickness (second degree) burns affecting up to 30% total body surface area.
Avita Medical Inc

NASDAQ:RCEL

RCEL Rankings

RCEL Latest News

RCEL Latest SEC Filings

RCEL Stock Data

115.91M
26.38M
0.87%
29.13%
22.03%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
VALENCIA